



# CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.  
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsLtd@gmail.com, web : www.concorddrugs.in

To,

Date: 14.02.2023

BSE Limited  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on 14.02.2023**

**Ref: Company's letter dated 02.02.2023**

**Unit: Concord Drugs Limited (Scrip Code: 538965)**

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Tuesday, 14.02.2023 at 4:30 P.M at the Registered office of the Company at Survey No.249, Brahmanapally Village, Hayatnagar Mandal-501511 Telangana., the following were considered and approved:

1. Unaudited Financial Results for the quarter ended 31.12.2022. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 31.12.2022. **(Enclosed)**
3. Appointment of Mr. Ankur Bisht as the Company Secretary and Compliance officer of the Company w.e.f.16.02.2023.

Disclosure as required under Reg. 30 of SEBI(Listing Obligations and Disclosure Requirements) 2015 is enclosed hereunder.

The meeting concluded at 5.30 pm.

Thanking you.

Yours sincerely,

For Concord Drugs Limited

*S. Nagi Reddy*

S. Nagi Reddy

Chairman and Managing Director

DIN: 01764665

Encl: as above



Seelam  
Nagi Reddy

Digitally signed by  
Seelam Nagi Reddy  
Date: 2023.02.14  
17:42:56 +05'30'

Disclosure under Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 related to appointments and resignation as mentioned below:

S. No	Details of events that need to be provided	Information of such event(s)
1.	Name of the Company Secretary	<b>Mr. Ankur Bisht</b>
2.	Reason for Appointment/Resignation	He is appointed as the Company Secretary and Compliance Officer of the Company w.e.f 16.02.2023
3.	Date of Appointment/Cessation and terms of appointment	Date of appointment- 16.02.2023 Term of appointment –same as KMP's
4.	Brief Profile (in case of appointment)	He is an Associate Member of ICSI and an MBA in Finance and has experience of more than 2 years in the Secretarial and legal matters.
5.	Disclosure of relationships between directors	He is not related to any Director or KMP and Promoters of the company.
6.	Shareholding, if any in the company	He is not holding any shares in the company.



Seelam  
Nagi Reddy

Digitally signed by  
Seelam Nagi Reddy  
Date: 2023.02.14  
17:43:36 +05'30'

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st December 2022

(Rs. in Lakhs)

Particulars	Quarterly ended			Nine months Ended		Year ended
	31-Dec-22 (UnAudited)	30-Sep-22 (unaudited)	31-Dec-21 (UnAudited)	31-Dec-22 (UnAudited)	31-Dec-21 (UnAudited)	31-Mar-22 (Audited)
<b>I Revenue from Operations</b>						
a. Net sales from Operations	1,352.71	1,371.56	1,344.17	3,977.42	4,349.29	5,895.65
b. Other Operating Income	0.12	0.09	2.77	0.81	7.72	10.00
<b>II Other Income</b>						
<b>III Total Revenue (I+II)</b>	<b>1,352.83</b>	<b>1,371.65</b>	<b>1,346.93</b>	<b>3,978.23</b>	<b>4,356.91</b>	<b>5,905.73</b>
<b>IV Expenses</b>						
a. Cost of Material Consumed	1,002.80	1,105.85	1,065.86	2,977.04	3,375.44	4,441.15
b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	-32.00	-31.31	15.75	-44.30	-37.99	-231.06
c. Employees Benefit Expenses	130.63	115.05	120.29	361.86	320.00	499.10
d. Finance Costs	44.92	42.05	10.31	120.79	144.62	160.07
e. Depreciation and Amortisation expense	37.97	52.69	29.51	129.53	139.35	176.45
f. Other expenses	106.03	63.43	29.39	231.09	189.22	637.21
<b>Total Expenses</b>	<b>1,291.23</b>	<b>1,347.76</b>	<b>1,289.12</b>	<b>3,867.41</b>	<b>4,139.64</b>	<b>5,600.92</b>
<b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>	<b>61.60</b>	<b>23.89</b>	<b>57.82</b>	<b>110.82</b>	<b>217.27</b>	<b>224.81</b>
<b>V Exceptional Items</b>						
<b>VI Profit/ (Loss) before tax (V-VI)</b>	<b>61.60</b>	<b>23.89</b>	<b>57.82</b>	<b>110.82</b>	<b>217.27</b>	<b>224.81</b>
<b>VII Tax Expense:</b>	<b>16.17</b>	<b>5.74</b>	<b>15.68</b>	<b>28.55</b>	<b>60.57</b>	<b>65.37</b>
<b>VIII a. Current tax</b>	<b>16.88</b>	<b>9.07</b>	<b>9.56</b>	<b>32.30</b>	<b>61.90</b>	<b>67.13</b>
<b>b. Deferred tax charge/credit</b>	<b>-0.51</b>	<b>-3.33</b>	<b>6.12</b>	<b>-3.84</b>	<b>-1.41</b>	<b>-1.75</b>
<b>IX Profit/ (Loss) for the period (VII-VIII)</b>	<b>45.43</b>	<b>18.15</b>	<b>42.14</b>	<b>82.27</b>	<b>156.70</b>	<b>159.44</b>
<b>X Other Comprehensive Income</b>						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b>	<b>45.43</b>	<b>18.15</b>	<b>42.14</b>	<b>82.27</b>	<b>156.70</b>	<b>159.44</b>
<b>XI Paid-up equity share capital</b> (Face value of the share- Rs. 10 each)	<b>874.38</b>	<b>874.38</b>	<b>874.38</b>	<b>874.38</b>	<b>874.38</b>	<b>874.38</b>
<b>Other Equity</b>	<b>2,147.60</b>	<b>1,998.57</b>	<b>1,958.95</b>	<b>2,147.60</b>	<b>1,958.95</b>	<b>1,961.00</b>
<b>XII Earnings per share (of Rs. 10 each)</b>						
<b>XIII a. Basic (in Rs)</b>	<b>0.52</b>	<b>0.21</b>	<b>0.48</b>	<b>0.94</b>	<b>1.79</b>	<b>1.82</b>
<b>b. Diluted (in Rs)</b>	<b>0.52</b>	<b>0.21</b>	<b>0.48</b>	<b>0.94</b>	<b>1.79</b>	<b>1.82</b>

## Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14th February, 2023
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company [www.concorddrugs.in](http://www.concorddrugs.in)

Place: Hyderabad  
Date: 14.02.2023

By Order of the Board  
For Concord Drugs Limited

*S. Nagi Reddy*  
S Nagi Reddy  
Chairman and Managing Director  
DIN: 01764665





# PUNDARIKASHYAM AND ASSOCIATES

## CHARTERED ACCOUNTANTS

D.No. 3-6-666, 3rd Floor, Barwale Chambers, Street No.11, Himayat Nagar,  
Hyderabad - 500 029, Cell : 9440464339, Ph : 040 - 40072693,  
E-mail: info@pkas.in / infoong@pkas.in / info.vizag@pkas.in

**GSTIN : 36AAJFP6218J1ZY**

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.  
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.  
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

### **Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

#### **To the Board of Directors of Concord Drugs Limited,**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 31 December 2022, and the year to date results for the period 1 April 2022 to 31 December 2022, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Pundarikashyam and Associates**

**Chartered Accountants**

**FRN: 011330S**

*B. Surya*



**B .Surya Prakasa Rao**

**(Partner)**

**MNo: 205125**

**Udin: 23205125BG52U13918.**

**Place: Hyderabad**

**Date: 14.02.2023**